A gene-based test for lung cancer risk assessment motivates smokers to quit or cut down, according to results of a clinical study presented at the American Association of Cancer Research’s 9th Annual Conference on Frontiers in Cancer Prevention Research.
Six months after taking the Respiragene test to identify susceptibility for lung cancer risk, 32% of the randomly recruited smokers in the study had quit smoking altogether and a further 48% had reduced their intake of cigarettes. More than half the smokers taking the risk test (63%) had used nicotine replacement products, the first line therapy recommended to help smokers quit. More than 90% of those who took the risk stratification test said they would recommend it to family and friends who smoked.
“These findings from this research support other studies showing gene-based risk testing of smokers leads to significantly reduced smoking rates,” said Robert Young, MD, associate professor of medicine and molecular genetics at Auckland University. “Current quit rates are pretty dismal. Given the number of lung cancer deaths each year, improving those quit rates must be a priority.”
Only about 4% to 7% of people are able to quit smoking on any given attempt without medicines or other help, according to the American Cancer Society. Although the link between smoking and lung cancer is well known—approximately 90% of lung cancers are diagnosed in current or former smokers—smoking rates remain static in many states in the United States despite ongoing public health initiatives.
“We found the results of the study very reassuring. The high rate of interest in taking Respiragene shows that smokers want to learn more about their own risk level, and for the vast majority, it helped them take positive steps to quit,” said Young. “These findings exceeded our expectation, especially as the participants in the study were randomly selected, and not specifically seeking support to quit smoking at the time of the study.”